We have recently shown that two-color analysis with fluorescein isothiocyanate (FITC)-anti-CD38 antibody could clearly distinguish myeloma cells (plasma cells) from other hematopoietic cells in the bone marrow. Myeloma cells (plasma cells) alone were located at CD38*'"g P -~~ I+ + ) fractions. To further distinguish normal plasma cells from mature myeloma cells phenotypically, we examined immunophenotypes of normal plasma cells and myeloma cells by two-color flow cytometry with FITC-anti-CD38 antibody and phycoerythrin staining with antibody to VIA-4, MPC-1, CD44, CD56, CD19, CD20, CD24, or CDIO. Normal plasma cells were all VIA-4+VLA-B+MPC-l +CD44+ CD19+CD56-in the bone marrows from seven healthy donors, tonsils from four patients with chronic tonsillitis, a spleen from one patient with idiopathic thrombocytopenic purpura, and lymph nodes from two patients with chronic lymphadenitis, respectively. On the other hand, mature myeloma cells (1 2 of 20 cases), VLA-4+VLA-5+MPC-l+, were all CD19-and most of them CD56+, and there were
ATURATION of B cells is accompanied by sequential
M acquisition and loss of characteristic cell surface antigens.' Plasma cells are characterized by expression of cytoplasmic Ig and surface membrane antigens associated with plasma cells such as PC-I, PCA-1, and CD38.2,3 However, the exact phenotype of normal plasma cells remains to be clarified, because normal plasma cells were so few in the bone marrow (BM) and lymph nodes that we could not evaluate their phenotype by single-color staining. So far, the phenotype of normal plasma cells is considered to be almost the same as that of myeloma cells or myeloma cell Recently, normal plasma cells were reported by immunogold-silver staining to be CD56-, whereas most myeloma cells were CD56+.8.9 By high-resolution flow cytometry, the phenotype of normal plasma cells has been characterized. Myeloid-specific antigens or early B-cell antigens were reported to be also expressed on normal plasma cells."
In this study, normal plasma cells as well as myeloma cells were clearly distinguished from other BM cells or lymphoid cells on two-color cytogram with fluorescein isothiocyanate (FITC)-anti-CD38 antibody staining. Plasma cells were found only in CD38Str0"g pos't've(++) fractions. We compared the phe- Tonsils from four patients with chronic tonsillitis, a spleen from one patient with idiopathic thrombocytopenic purpura (ITP), and lymph nodes from two patients with chronic lymphadenitis were also studied. Informed consent was obtained from all patients before these procedures.
BM mononuclear cells were freshly isolated from BM aspirates by Ficoll-Hypaque density gradient centrifugation as described previously. For personal use only. on August 16, 2017. by guest www.bloodjournal.org From flow cytometer (Cytron: Ortho Diagnostic Systems, Raritan. NJ). Two-color flow cytograms with FITC-anti-CD38 (x-axis, log scale) and PE-staining (y-axis. log scale) were presented.
The cells were stained with FITC-antLCD38 and PE-staining as described above. Cell sorting was performed by a cell sorter (FACS-IV; Becton Dickinson). The sorted cells were cytospun and stained with Wright's solution.
Cell sorting.

RESULTS
Mononuclear cells were isolated from BM, tonsils, spleen, or lymph nodes, and stained with FITC-anti-CD38 and PEanti-VLA-5 antibody. The CD38++ cells were sorted by a cell sorter (FACS-IV) and stained with Wright's solution. In healthy donors, normal plasma cells were located at the CD38++ fractions. The cells sorted from CD38++ fractions were all plasma cells morphologically, as shown in Fig lA, but the cells sorted from CD38-or CD3SWeak posit've (+) contained almost no plasma cells. In myeloma patients, the cells with CD38++VLA-5+ were also sorted and their morphology was examined under microscope. Figure 1B shows that the cells sorted from CD38++VLA-5' were morphologically mature myeloma cells according to Greipp's classification. " CD38" fractions and CD19' B cells in the BM existed in the mononuclear cell fractions (Fig 2A) , but not in the other remaining fractions (Fig 2B) of the forward and right scattering profile. The percentage of myeloma cells or plasma cells in BM mononuclear cells based on morphologic examination were almost the same as that of CD38++ fractions by flow cytometry. Therefore, it was confirmed that normal plasma cells as well as myeloma cells were located at the CD38" fractions on two-color cytogram with FITC-anti-CD38 antibody staining.
The phenotypes of myeloma cells from 20 myeloma patients were studied ( Table l) . Myeloma cells from patients no. 1 through I2 showed their phenotype to be VLA-4+VLA-5'MPC-1' and were all mature myeloma cells, whereas myeloma cells from patients no. 13 through 20 were immature myeloma cells (VLA-4+VLA-5-MPC-1 -). as demonstrated recentIy. 16 As for expression of CD56 and CD19, myeloma cells in most patients ( 1 3 of 20 cases), mature and immature myeloma cells, were CD56+CD 19-, as shown in Fig 3B; Table I were CD56-CD19-, as shown in Fig 3A; and myeloma cells in 2 cases (patients no. 13 and 14 in Table 1) were CD56+CD 19' . However, there were not any myeloma cells with their phenotype of CD56-CD19+.
Normal plasma cells were harvested from BM aspirates in 7 healthy donors, from tonsils of 4 patients with chronic tonsillitis, from the spleen of a patient with ITP, from the lymph nodes of two patients with chronic lymphadenitis, as described in Materials and Methods. Normal plasma cells in various tissues were all VLA-4'VLA-S'MPC-1+ CD44'CDWCD 19' (Table 1) . Two-color cytograms of normal plasma cells were shown in Furthermore, the expression of other B-cell-lineage antigens was also examined on normal plasma cells. All of the normal plasma cells we tested showed the CD20-CD24-CD 10-phenotype (Table 1 ). This phenotype was almost the same as that of myeloma cells, although there were only a few myeloma cells with the CD20' phenotype.
Our data clearly show that the CD38++CD56-CD 19' phenotype is found only on normal plasma cells in various tissues such as BM, tonsils, spleen, and lymph nodes, because there were no myeloma cells with the CD38++CD56-CD19+ phenotype in myeloma patients.
Additionally, we examined the expression of CD 19 and CD56 on plasma cells in 5 cases of MGUS ( Table 1) . Plasma 
CD38
The other remaining fractions.
clearly distinguish normal plasma cells from mature myeloma cells. The CD56 antigen is reported to be expressed on NK cells and a subset of T cells." Recent studies showed that the expression of CD56 was also found on myeloid leukemia cells, trophoblast cells, sea urchin coelomonocytes, small cell lung cancer cells, and neural Furthermore, CD56 antigen is also found to be identical to the 140-Kd isoform of N-CAMZo and to be the adhesion molecule that binds each other (homophilic binding).2' The biologic role of CD56 molecule expressed on most myeloma cells, but not on normal plasma cells is still unclear. However, it is possible that CD56 molecule may be involved in the interaction between myeloma cells and BM stromal cells. BM stromal cells were recently shown to express CD56 antigenZ2 and CD56 is one of the adhesion molecules that induce homophilic adhesion, as described above. Also, it was observed that some myeloma cells attached to BM stromal cells or a stromal cell line (KM-102) and could survive for a long time.23 However, CD56 molecule alone is not enough to explain adhesion of myeloma cells to BM stromal cells, but several other adhesion molecules may be involved in such interaction. Our recent work shows that expression of one of the adhesion molecules (VLA-5) could define mature myeloma cells,16 and a monoclonal antibody (MPC-1) that we established could divide mature myeloma cells into subtypes. More mature myeloma cells were VLA-5+MPC-1+.I4 VLA-5 molecule may be one ofthe molecules responsible for adhesion of myeloma cells to BM stromal cells. There is no apparent correlation between CD56 and VLA-5 or MPC-I expression on myeloma cells, as shown in Table I A part of cells weakly expressed.
t Both positive and negative cells were found, and negative fraction was dominant.
* Both positive and negative cells were found, and positive fraction was dominant.
CD19 antigen has been considered to be the antigen of Bcell lineage and to be lost during terminal differentiation of B cells into plasma ~e l l s .~~,~~ Surprisingly, in this report, normal plasma cells from various tissues were all CD 19' . Therefore, CD 19 is one of the important markers that define normal plasma cells. Two-color analysis with FITC-anti-CD38 antibody made it possible to examine the phenotype of normal plasma cells exactly, even though there were not more than 1% plasma cells in the BM samples from healthy donors. The biologic role of CD 19 expression on normal plasma cells not comprising mostly myeloma cells remains unclear.
Furthermore, it is of interest that, phenotypically, both normal plasma cells with CD56-CD19' and malignant cells are found in MGUS. MGUS is clinically stable and biologically a low labeling index, but a part of MGUS develops malignant transformation after long periods; MGUS is considered to be a socalled premyeloma state. 26 This finding that MGUS consist of normal plasma cells and malignant malignant cells (myeloma cells) could provide some clue as to the mechanism of malignant transformation into myeloma cells. We are now investigating the biologic and molecular difference between CD56-CD 19+ and CD56TD19-cells in MGUS.
In conclusion, we can clearly detect normal plasma cells by two-color analysis with HTC-anti-CD38 antibody and PE-anti-CD56 or PE-anti-CD19 antibody, even though very few plasma cells are present in the BM samples from plasma cell dyscrasia. We provide here the phenotypic evidence that normal plasma cells are all CDWCD19+, and that this phenotype is not found on any myeloma cells. The presence of normal plasma cells and malignant plasma cells (myeloma cells) in MGUS will contribute to the further study on oncogenesis of myelomas.
